[Geriatrics].
A new vaccine reduces the incidence and severity of zoster and its complications in older persons. A cost-effectiveness analysis highlights the implication of CDC's recent recommendation to vaccinate all persons aged 60 years and over. A meta-analysis confirms that the chronic use of sedatives in older persons provides modest benefits and important risks. Unfortunately, melatonin does not seem to be a useful alternative. A systematic review of interventions to prevent pressure ulcers provides scientific support to measures empirically used in most institutions. Finally, a randomized controlled trial questions the clinical benefit of atypical neuroleptics in Alzheimer's disease and a comprehensive review of pharmacological trials in mild cognitive impairment reports no benefit of any of the tested drugs on conversion rate to Alzheimer's disease.
Büla
C
C
Service de gériatrie et readaptation gériatrique, Centre universitaire de traitements et de readaptation (CUTR) Sylvana, Département de médecine, CHUV CUTR Sylvana, 1066 Epalinges. christophe.bula@chuv.ch
Gold
G
G
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D003072:Cognition Disorders / Q000188:drug therapy; D005853:Geriatrics; D006562:Herpes Zoster / Q000517:prevention & control; D053061:Herpes Zoster Vaccine; D006801:Humans; D003668:Pressure Ulcer / Q000517:prevention & control; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy
D053061:Herpes Zoster Vaccine